Health Care & Life Sciences » Biotechnology | Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
5,276.00
25,404.00
47,453.00
113,747.00
56,147.00
72,627
Depreciation, Depletion & Amortization
26.00
162.00
812.00
1,603.00
2,096.00
1,750
Other Funds
-
-
427.00
393.00
313.00
18,534
Funds from Operations
2,105.00
15,694.00
34,117.00
40,006.00
44,665.00
53,593
Changes in Working Capital
70.00
10,046.00
1,221.00
1,640.00
756.00
371
Net Operating Cash Flow
2,175.00
5,648.00
35,338.00
38,366.00
45,421.00
53,964
Capital Expenditures
91.00
943.00
2,992.00
2,412.00
1,016.00
Sale of Fixed Assets & Businesses
-
-
-
3,449.00
-
Purchase/Sale of Investments
-
-
38,577.00
37,738.00
121,188.00
Net Investing Cash Flow
91.00
943.00
41,569.00
38,775.00
122,204.00
Issuance/Reduction of Debt, Net
1,500.00
540.00
-
-
-
Net Financing Cash Flow
2,480.00
165,442.00
138,860.00
556.00
16,748.00
Net Change in Cash
207.00
158,840.00
61,944.00
822.00
151,651.00
Free Cash Flow
2,266.00
6,591.00
38,330.00
40,778.00
46,437.00
Change in Capital Stock
980.00
165,982.00
139,287.00
949.00
17,061.00
Exchange Rate Effect
7.00
11.00
9.00
143.00
774.00

About Adverum Biotechnologies

View Profile
Address
1035 O'Brien Drive
Menlo Park California 94025
United States
Employees -
Website http://www.adverum.com
Updated 07/08/2019
Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.